Results of an open-label study of high-dose liposomal amphotericin B (AmBisome) in the treatment of confirmed fungal infections in high-risk patients

被引：0
|
作者：
Kinsey, S
Jackson, G
Holyoake, T
McCann, S
Gibson, B
机构：
[1] St James Hosp, Dept Paediat Haematol, Leeds LS9 7TF, W Yorkshire, England
[2] Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
[3] Glasgow Royal Infirm, Dept Haematol, Glasgow G4 0SF, Lanark, Scotland
[4] St James Hosp, Dept Haematol, Dublin 8, Ireland
[5] Royal Hosp Sick Children, Dept Haematol, Glasgow G3 8SJ, Lanark, Scotland
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2004年 / 125卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
202
引用
收藏
页码：62 / 63
页数：2
相关论文
共 50 条
  • [31] Amphotericin B lipid complex (ABLC) for fungal sepsis in high-risk immunocompromised patients
    Mehta, J
    Powles, R
    Singhal, S
    Jameson, B
    Treleaven, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1221 - 1221
  • [32] A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study
    Thakur, CP
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (01) : 67 - 70
  • [33] Results of High-Dose Treosulfan-Containing Regimen in Patients With High-Risk Neuroblastoma
    Shamanskaya, T.
    Kachanov, D.
    Hachatryan, L.
    Khismatullina, R.
    Moiseenko, R.
    Teleshova, M.
    Skorobogatova, E.
    Druy, A.
    Zemcova, L.
    Kurnikova, E.
    Tereschenko, G.
    Nechesnyuk, A.
    Akhaladze, D.
    Fomin, D.
    Konovalov, D.
    Grachev, N.
    Likar, Y.
    Maschan, M.
    Varfolomeeva, S.
    Novichkova, G.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S170 - S170
  • [34] LIPOSOMAL AMPHOTERICIN-B FOR THE TREATMENT OF SYSTEMIC FUNGAL-INFECTIONS IN PATIENTS WITH CANCER - A PRELIMINARY-STUDY
    LOPEZBERESTEIN, G
    FAINSTEIN, V
    HOPFER, R
    MEHTA, K
    SULLIVAN, MP
    KEATING, M
    ROSENBLUM, MG
    MEHTA, R
    LUNA, M
    HERSH, EM
    REUBEN, J
    JULIANO, RL
    BODEY, GP
    JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (04): : 704 - 710
  • [35] AMBIZYGO:: phase II study of high dose liposomal amphotericin B (AmBisome®) [10 mg/kg/j] efficacy against zygomycosis
    Lanternier, F.
    Lortholary, O.
    MEDECINE ET MALADIES INFECTIEUSES, 2008, 38 : S90 - S91
  • [36] Liposomal amphotericin B standard dose in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocompromised patients:: randomised pilot study (Combistrat Trial)
    Caillot, D.
    Thiebaut, A.
    Herbrecht, R.
    Pigneux, A.
    de Botton, S.
    Attal, M.
    Bernard, F.
    Larche, J.
    Alfandari, S.
    Monchecourt, F.
    Mahi, L.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S260 - S260
  • [37] High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients
    Bertuzzi, A
    Gullo, G
    Rimassa, L
    Castagna, L
    Santoro, A
    ANNALS OF ONCOLOGY, 2006, 17 (04) : 719 - 720
  • [38] Alirocumab in high-risk patients: Observations from the open-label expanded use program
    Glueck, Charles J.
    Brown, Alan
    Goldberg, Anne C.
    McKenney, James M.
    Kantaros, Louis
    Stewart, John
    Elassal, Joseph
    Koren, Andrew
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 662 - 668
  • [39] The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study
    Rubin-Kahana, Dafna Sara
    Shelef, Assaf
    Weizman, Abraham
    Gothelf, Doron
    Timinski, Igor
    Spivak, Baruch
    Stryjer, Rafael
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (04) : 179 - 183
  • [40] Treatment of confirmed and suspected invasive fungal infections with liposomal amphotericin B in patients with a hemtological malignancy in a tertiary care hospital in 1991-2000
    Salonen, JH
    Remes, K
    Salmi, TT
    Nikoskelainen, J
    BONE MARROW TRANSPLANTATION, 2002, 29 : S248 - S248
12345